Stock Spotlight: Nufarm Ltd (ASX:NUF)

About Nufarm Ltd

Nufarm Limited, together with its subsidiaries, develops, manufactures, and sells crop protection solutions and seed technologies in Europe, the Middle East, Africa, North America, and the Asia Pacific. The company operates through Crop Protection and Seed Technologies segments. The company offers herbicides, insecticides, and fungicides that help growers protect crops against weeds, pests, and diseases. It also operates base seeds, bioenergy, omega-3 and seed treatment platforms, as well as sells seeds and oil-based products. It also focuses on crops, such as cereals; corn; soybean; pasture, turf, and ornamentals; and trees, nuts, vines, and vegetables. In addition, the company provides seed treatment products for the protection and treatment of damage caused by insects, fungus, and disease. Further, it distributes sunflower, sorghum, and canola seeds. The company was founded in 1916 and is headquartered in Laverton North, Australia.



Key Stats

Source: Yahoo Finance. Data as of 15/08/25.

Price Performance

Growth Potential

  • FY26 is expected to benefit from cost savings and new product introductions, with net debt reduction expected to operate within the target leverage range of 1.5-2x underlying EBITDA.
  • Strong cash generation driven by inventory reduction which combined with reduction in rate of capex (FY25 expected to be peak) should translate to potentially increased shareholder returns.
  • Ongoing focus on operational efficiency to support earnings (working to optimize production zones and supply routes to reduce logistics and stewardship costs with optimization of direct-to-crush production zones having already led to a 9% reduction in logistics costs in 2025, with further reductions expected in 2026 and 2027).
  • Continued advancement of cost of goods reduction as active ingredient prices have generally stabilized and management has reduced grower premiums by -37% in their 2025 contracts, enabling cost of goods reduction for oil sales in 2026.
  • Strong pipeline of differentiated products with several key products anticipated to launch by 2028 (secured rights to develop a new proprietary broad spectrum non-selective herbicide, targeting a launch in the Australian market before 2030).
  • Sector consolidation could see NUF potentially engaged in corporate activity.


Key Risks

  • Integration risk associated with recent acquisitions.
  • Adverse movements in commodities prices and currencies.
  • Unfavorable seasonal impacts.
  • Competitive pressures.
  • Regulatory / litigation risks.
  • Unfavorable cost of capital due to credit rating downgrade (credit rating has been placed on watch negative from outlook negative by S&P with expectation of earnings remaining unpredictable over the next one to two years).

Subscribe to our newsletter

Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.

Speak to an Advisor

November 4, 2026
The RBA lifted the cash rate to 4.85% in a split vote. Here’s how higher rates flow through ASX sectors, company earnings, dividends and valuations.
October 29, 2026
Inside Anthropic’s IPO filing: explore its soaring revenue, computing commitments, reported losses and governance structure, and what the disclosures mean for investors.
October 21, 2026
Big Tech reports next week. Learn how to read earnings releases and filings, and what to look for in AI spending, cloud growth, cash flow and guidance.
October 14, 2026
Understand how AI investment could affect global financial stability, as the IMF and RBA warn of rising debt, market concentration and funding risks.
October 8, 2026
Firmus’ proposed mega-IPO puts a spotlight on the cost, capital intensity and risks of building AI infrastructure as investors weigh the next phase of the AI boom.
October 6, 2026
About Electro Optic Systems Holdings Ltd. Electro Optic Systems Holdings Limited engages in the development, manufacture, and sale of telescopes and dome enclosures, laser satellite tracking systems, remote weapon systems, and high laser weapon. It operates through Defense Systems and Space Systems segments. The company develops, manufactures, and markets fire control, surveillance, weapon systems, and high energy laser to military customers. It also provides passive optical and laser sensing equipment; optical, microwave and on-the-move radio and satellite products; and laser-based surveillance systems with space tracking capability. In addition, the company offers counter-drone, firepower, force protection, and UGV and marine lethality systems, as well as high energy laser weapon; optical tracking systems, space control, space domain awareness, satellite laser ranging, space sustainability, and precision optics. It operates in Australia, the United States, Singapore, the United Arab Emirates, the United Kingdom, New Zealand, the Netherlands, North America, Germany, and rest of Europe. Electro Optic Systems Holdings Limited was founded in 1983 and is based in Symonston, Australia. Source: EODHD Key Stats
October 6, 2026
About Liontown Ltd. Liontown Limited engages in the exploration, evaluation, and development of mineral properties in Australia. It primarily explores for lithium, gold, and nickel deposits. The company's flagship property is the Kathleen Valley lithium project located in Perth, Western Australia. The company was formerly known as Liontown Resources Limited and change its name to Liontown Limited in November 2025. Liontown Limited was incorporated in 2006 and is headquartered in West Perth, Australia. Source: EODHD Key Stats
September 30, 2026
The RBA has raised rates to 4.60% as inflation pressures persist. Explore the impact of energy costs, AI demand and the key signals investors should watch next.
September 22, 2026
Discover how advances in genomics, AI, diagnostics and gene editing are creating a broader healthcare opportunity and where commercial value is emerging.
September 15, 2026
The AI trade is being forced to rethink the pace of progress. Here is what investors should watch across Nvidia, chips, AI spending, software and adoption.